For treating ROS1-positive advanced non-small-cell lung cancer (TA1021)

Funded by NHS England indications:
Everolimus with lenvatinib for previously treated advanced renal cell carcinoma (NICE TA498)
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Non-commissioned indications:
Cardiac Transplantation (rejection)
Renal Transplantation (rejection)
Renal Cell Carcinoma (advanced 2nd line treatment)
Prevention of organ rejection in people having a liver transplant (NICE TA348)

For treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least 1 line of systemic treatment

For treating polycythaemia vera in adults who cannot tolerate hydroxycarbamide

For treating HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who have had:
1. an anthracycline or a taxane, or both, unless these treatments are not suitable, and
2. endocrine therapy if they have hormone receptor (HR)-positive breast cancer, unless this is not suitable (NICE TA952).